Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 18/20 | 0.83 |
| ▸ | ERBB3 | P21860 | 17/20 | 0.83 |
| ▸ | ERBB4 | Q15303 | 17/20 | 0.83 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3506331 | 0.94 | EGFR (0.78) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL3505765 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB3ERBB4FGFR1 | |
| SCHEMBL2749410 | 0.88 | EGFR (1.00) | EGFRERBB2ERBB3ERBB4 | |
| Hydrochloric Acid SCHEMBL3505227 | 0.88 | EGFR (0.65) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL3506524 | 0.83 | EGFR (0.59) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL3505139 | 0.83 | EGFR (0.69) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL2747770 | 0.82 | EGFR (0.83) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL3506623 | 0.82 | EGFR (0.87) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL3506777 | 0.81 | EGFR (0.79) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL986656 | 0.79 | EGFR (1.00) | EGFRERBB2ERBB3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216788-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216788-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216788-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| WO-2007064045-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216788-A1 | FUSED HETEROCYCLIC COMPOUND | GRK6, FGFR1, PTK6 | EGFR 54/4885ERBB2 31/4885ERBB3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.